Jean Marc Phelip

Erratum: A 6-Thioguanine Nucleotide Threshold Level of 400 pmol/8×108 Erythrocytes Predicts Azathioprine Refractoriness in Patients With Inflammatory Bowel Disease and Normal TPMT Activity

BACKGROUND AND AIMS:A therapeutic level of 6-thioguanine nucleotides (6-TGN) has been reported in inflammatory bowel disease (IBD) patients under azathioprine (AZA). We investigated the threshold value of 6-TGN that may be predictive of AZA refractoriness and its impact on safety profile.METHODS:Patients with normal thiopurine methyltransferase (TPMT) activity (7.5–14 U/mL erythrocytes), suffering from steroid-dependent or active IBD despite AZA use for at least 6 months, were prospectively included. Clinical efficacy, adverse events, and thiopurine metabolite levels were recorded at baseline, 1 month after each dose escalation, and thereafter every 3 months.RESULTS:Fifty-five patients were included (43 with Crohns disease, 12 with ulcerative colitis). After a mean follow-up of 12 months, 31 patients (56.3%) did not reach clinical remission despite a gradual increase in AZA dose and 6-TGN level of >400 pmol/8 × 108 erythrocytes, and were considered refractory to AZA (sensitivity 45%, specificity 100%). Adverse events occurred more frequently in these patients than in responders (42% vs 25%, respectively, P = 0.02). Among 55 patients, 15 cases of myelotoxicity associated with elevated levels of total methylated metabolites (14,500 pmol/8 × 108 erythrocytes vs 5,230 pmol/8 × 108 erythrocytes in patients without myelotoxicity, P = 0.03) were observed. Patients with total methylated metabolites of >11,100 pmol/8 × 108 erythrocytes had an increased risk of developing myelotoxicity (odds ratio [OR] 11.0, 95% confidence interval [CI] 1.1–250, P = 0.05).CONCLUSION:A 6-TGN level of >400 pmol/8 × 108 erythrocytes in IBD patients with normal TPMT activity and steroid-dependent or active disease despite an optimal AZA regimen may predict refractoriness to this drug. Furthermore, high levels of methylated derivatives are associated with an increased risk of myelotoxicity.

Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease

Background: Folate deficiency associated with hyperhomocysteinemia might increase the risk of developing colorectal cancer. The aim of this study was to evaluate factors associated with colonic carcinogenesis, in particular, folate and homocysteinemia levels, in a cross‐sectional study of patients with inflammatory bowel disease (IBD). Methods: IBD patients with carcinogenic lesions discovered during colonoscopy [dysplasia‐associated lesion or masses (DALM), colorectal cancer] were included and compared with the whole population of IBD patients with a normal colonoscopy performed during the same period. The following parameters were collected at the time of colonoscopy: age, sex, type, duration, activity, and extent of the disease, treatment, smoking status, and vitamin B12, folate, and homocysteinemia levels. Univariate and multivariate analyses were performed after adjusting for the main parameters. Results: One hundred and fourteen patients [41 with ulcerative colitis (UC), 73 with Crohns disease (CD)] were included. Twenty‐six carcinogenic lesions were isolated: 18 DALM (7 high‐grade and 11 low‐grade dysplasia) and 8 colorectal cancers. In univariate analysis, the factors associated with carcinogenesis were: active smoking (P = 0.03), folate level < 145 pmol/L (P = 0.02), hyperhomocysteinemia > 15 &mgr;mol/L (P = 0.003), duration of disease > 10 years (P = 0.006), and UC (P = 0.02). In multivariate analysis, patients with hyperhomocysteinemia associated with folate deficiency had 17 times as many carcinogenic lesions as patients with normal homocysteinemia whatever the folate status and duration of the disease (P = 0.01). Patients with hyperhomocysteinemia without folate deficiency had 2.5 times as many carcinogenic lesions as patients with normal homocysteinemia (P = 0.08). Conclusions: Our data suggest that in IBD patients with normal homocysteinemia, the increase in carcinogenic risk is negligible. Conversely, in patients with hyperhomocysteinemia, folate deficiency may be associated with increased colorectal carcinogenesis in IBD patients.

L’estomac pastèque : une cause rare d’anémie ferriprive, de traitement chirurgical ; un nouveau cas et revue de la littérature

Resume Les auteurs rapportent un nouveau cas d’estomac pasteque non associe a une hypertension portale, et responsable d’une anemie ferriprive chronique corrigee par une antrectomie. L’estomac pasteque est une forme d’ectasie vasculaire antrale avec un aspect endoscopique caracteristique. A partir d’une revue de la litterature, le diagnostic, l’histologie, la pathogenie et le traitement de l’estomac pasteque sont rappeles.

Is ulcerative colitis proctitis associated with an increased risk of colorectal cancer

1. Tamura S, Sugawara Y, Kukudo N, et al. Systematic grading of morbidity after living donation for liver transplantation. Gastroenterology 2008;135:1804. 2. Adult-to-adult living donor liver transplantation cohort study (A2ALL). Hepatology 2003;38:792. 3. Freis C, Ghobrial RM; A2ALL study group. Response to letter “Systematic grading of morbidity after living donation for liver transplantation.” Gastroenterology 2009;137:1855–1856. 4. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–213. 5. Ghobrial RM, Freise CE, Trotter JF, et al. Donor morbidity after living donation for liver transplantation. Gastroenterology 2008;135:468– 476. 6. Haga J, Shimazu M, Wakabayashi G, et al. Liver regeneration in donors and adult recipients after living donor liver transplantation. Liver Transpl 2008;14:1718–1724. 7. Seda-Neto J, Godoy AL, Carone E, et al. Left lateral segmentectomy for pediatric live-donor liver transplantation: special attention to segment IV complications. Transplantation 2008;86:697–701. 8. DeOliveira ML, Winter JM, Schafer M, et al. Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg 2006;244:931–937. 9. Patel S, Cassuto J, Orloff M, et al. Minimizing morbidity of organ donation: analysis of factors for perioperative complications after living-donor nephrectomy in the United States. Transplantation 2008;85:561–565. 0. SurgicalComplication.info.com [homepage on the Internet]. Available: http://www.surgicalcomplication.info/index-6.html. Accessed May 15, 2009.

Biological Plausibility Between Proton Pump Inhibitory Therapy and Hip Fracture: Hypermocysteinemia Can Be the Link

Biological Plausibility Between Proton Pump Inhibitory Therapy and Hip Fracture: Hypermocysteinemia Can Be the Link